ANHUI WANBANG PHARMACEUTICAL TECHNOLOGY CO., LTD. Anhui Wanbang Pharmaceutical Technology Co., Ltd. Stock
Equities
301520
CNE1000068J8
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.18 CNY | -1.51% |
|
-0.10% | -25.53% |
| Sales 2022 | 261M 35.86M | Sales 2023 | 342M 47M | Capitalization | 3.69B 507M |
|---|---|---|---|---|---|
| Net income 2022 | 98M 13.47M | Net income 2023 | 108M 14.85M | EV / Sales 2022 * | - |
| Net cash position 2022 | 186M 25.62M | Net cash position 2023 | 1.16B 159M | EV / Sales 2023 | 7.4 x |
| P/E ratio 2022 * |
-
| P/E ratio 2023 |
27.7
x | Employees | 160 |
| Yield 2022 * |
-
| Yield 2023 |
0.9% | Free-Float | 24.38% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.51% | ||
| 1 week | -0.10% | ||
| Current month | -0.48% | ||
| 1 month | -8.89% | ||
| 3 months | -17.39% | ||
| 6 months | -24.18% | ||
| Current year | -25.53% |
1 week
40.57
42.38
1 month
40.3350.75
Current year
40.3360.48
1 year
40.3390.00
3 years
40.3390.00
5 years
40.3390.00
10 years
40.3390.00
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-02 | 41.18 | -1.51% | 685,952 |
| 24-07-01 | 41.81 | +1.04% | 724,872 |
| 24-06-28 | 41.38 | +0.49% | 755,723 |
| 24-06-27 | 41.18 | -2.65% | 877,549 |
| 24-06-26 | 42.3 | +2.62% | 1,153,436 |
End-of-day quote Shenzhen S.E., July 01, 2024
More quotes
Anhui Wanbang Pharmaceutical Technology Co Ltd is a China-based company primarily engaged in the provision of pharmaceutical research and clinical research services as a comprehensive contract research organization (CRO). The Company mainly provides professional pharmaceutical research and development outsourcing services to pharmaceutical companies and other pharmaceutical research and development institutions. The Company's services mainly include pharmaceutical research services such as generic drug development and consistency evaluation services, as well as clinical research services such as clinical trial operations, clinical trial site management, biological sample analysis, data management and statistical analysis. The Company mainly operates its businesses in the domestic market.
| 1st Jan change | Capi. | |
|---|---|---|
| -25.53% | 378M | |
| +17.72% | 44.87B | |
| -10.33% | 37.8B | |
| +41.87% | 37.61B | |
| +29.36% | 31.32B | |
| -8.44% | 27.4B | |
| +12.45% | 26.32B | |
| +44.19% | 14.07B | |
| +31.93% | 12.5B | |
| -7.67% | 11.23B |
- Stock Market
- Equities
- 301520 Stock
